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Highlights 
 Whole-genome RNAi synthetic sickness/lethality screens were performed. 
 We identified synthetic sickness/lethality interaction of RRM1 with REV3. 
 HU and iREV3 treatments synergistically induce single-stranded DNA in S-phase. 
 This increase is not accompanied by accumulation of DNA damage. 
 Our findings indicate that REV3 plays a role in coping with DNA replication stress. 
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ABSTRACT 
REV3, the catalytic subunit of translesion polymerase zeta (polδ), is commonly associated with DNA 
damage bypass and repair. Despite sharing accessory subunits with replicative polymerase δ, very little is 
known about the role of polδ in DNA replication. We previously demonstrated that inhibition of REV3 
expression induces persistent DNA damage and growth arrest in cancer cells. To reveal determinants of 
this sensitivity and obtain insights into the cellular function of REV3, we performed whole human genome 
RNAi library screens aimed at identification of synthetic lethal interactions with REV3 in A549 lung cancer 
cells. The top confirmed hit was RRM1, the large subunit of ribonucleotide reductase (RNR), a critical 
enzyme of de novo nucleotide synthesis. Treatment with the RNR-inhibitor hydroxyurea (HU) 
synergistically increased the fraction of REV3-deficient cells containing single stranded DNA (ssDNA) as 
indicated by an increase in replication protein A (RPA). However, this increase was not accompanied by 
accumulation of the DNA damage marker γH2AX suggesting a role of REV3 in counteracting HU-induced 
replication stress (RS). Consistent with a role of REV3 in DNA replication, increased RPA staining was 
confined to HU-treated S-phase cells. Additionally, we found genes related to RS to be significantly 
enriched among the top hits of the synthetic sickness/lethality (SSL) screen further corroborating the 
importance of REV3 for DNA replication under conditions of RS. 
Keywords: REV3, polymerase zeta, replication stress, translesion synthesis, DNA damage 
Abbreviations: ANOVA, analysis of variance; CDDP, cisplatin; DDR, DNA damage response; HU, 
hydroxyurea; Polδ, polymerase zeta; RNR, ribonucleotide reductase; RPA, replication protein A; RS, 
replication stress; ssDNA, single-stranded DNA; SSL, synthetic sickness/lethality; TLS, translesion 
synthesis 
1. Introduction 
Integrity and fidelity of the genomic material is constantly compromised in various ways but cells possess 
multiple mechanisms to cope with it (Jackson and Bartek, 2009). If DNA damage cannot be repaired, it 
can be tolerated in order to continue replication without formation of lethal intermediates. Translesion 
synthesis (TLS) is a key DNA damage tolerance pathway that allows bypass of different types of lesions. 
Dependent on the nature of the lesion and recruited enzymes, this process can result in faithful or error-
prone, i.e. mutagenic, DNA replication (reviewed in (Knobel and Marti, 2011)). 
Polymerase zeta (polδ), with its catalytic subunit REV3L (hereafter REV3), plays a unique role in TLS. 
REV3 is able to contribute to mutagenesis in two ways: by introducing mismatches or by extending from a 
mismatch introduced by another polymerase. Besides, in contrast to other TLS polymerases, REV3 
belongs to the B-family and its knockout is embryonic lethal in mice (Esposito et al., 2000; Wittschieben et 
al., 2000). Despite the development of conditional knockout mice models, (Lange et al., 2013; 
Wittschieben et al., 2010) the molecular basis for this developmental significance still remains elusive. 
Apart from its function in TLS, polδ is known to play a role in homologous recombination (Sharma et al., 
2012), non-homologous end-joining (Covo et al., 2009) and inter- and intrastrand crosslink repair (Enoiu et 
al., 2012; Hicks et al., 2010). Additionally, yeast polδ is able to replicate undamaged DNA (Northam et al., 
2010) and shares accessory subunits with polymerase δ (Johnson et al., 2012; Makarova et al., 2012) 
emphasizing its tight relationship with normal DNA replication. Inhibition of REV3 expression in human 
cells leads to accumulation of DNA double strand breaks (DSB), activation of DNA damage response 
(DDR) and a reduced fraction of S-phase cells (Knobel et al., 2011), which results in increased formation 
of anaphase bridges and chromosomal breaks/gaps, expression of common fragile sites (CFS), genomic 
instability (Bhat et al., 2013) and ultimately cell cycle arrest or senescence (Knobel et al., 2011).  
Cancer cells harbor multiple mutations in their genome, many of which affect DDR and lead to genomic 
instability but can be tolerated because of the redundant or complementary function of some of the DNA 
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repair pathways (Jackson and Bartek, 2009). Thus, targeting genes whose function becomes essential 
due to mutations in cancer cells is an attractive approach to cancer therapy (Kaelin, 2005). This so-called 
principle of synthetic sickness/lethality (SSL) demonstrated its applicability for targeted cancer therapy of 
BRCA2-deficient breast cancer by PARP-inhibitors not only at the bench (Bryant et al., 2005; Farmer et 
al., 2005) but also at the bedside (Fong et al., 2009). Recent publications follow this example by 
discovering synthetic lethality between MSH2 and DNA polymerase β (POLB), MLH1 and polymerase γ 
(POLG) (Martin et al., 2010) as well as Chk1 and polymerase λ (POLL) (Zucca et al., 2013), confirming 
that SSL between DDR genes is a common phenomenon. 
Loss-of-function genetic screening is a powerful approach for novel target gene discovery that can be 
employed for detection of synthetic lethal gene interactions in cancer cells (reviewed in (Mullenders and 
Bernards, 2009; Nijman, 2011)). In particular, RNA interference technology was successfully used to 
identify vulnerabilities of cancers driven by certain oncogenes (Luo et al., 2009). Here, we took advantage 
of a whole human genome siRNA library to explore in an unbiased manner SSL in REV3-deficient cancer 
cells, in order to gain insight into cellular functions of REV3. 
2. Material and methods 
2.1. Cell culture, plasmid transfections, gene expression analysis 
The non-small cell lung cancer (NSCLC) cell line A549 was authenticated by DNA fingerprinting of short 
tandem repeat loci (Microsynth, Switzerland). Stable cell lines used for the siRNA screening were 
generated by transfection of A549 cells with either the scrambled short hairpin RNA (shRNA) expressing 
plasmid shSCR or the REV3-silencing shRNA expression plasmid shREV3-4 (Knobel et al., 2011). 
Plasmid transfections were performed using Lipofectamine
TM
 2000 (Invitrogen) according to the 
manufacturer’s instructions. Subsequent selection of resistant clones was performed with 1ug/ml 
puromycin. Gene knockdown was assessed by quantitative real-time PCR (rtPCR) measuring ΔΔCt 
values of the target gene versus control Histone H3 as described previously (Knobel et al., 2011). All cell 
lines were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) high glucose (Sigma) supplemented 
with 2 mM L-glutamine, 10% fetal calf serum (FCS) and 1% (w/v) penicillin/streptomycin. Cells were grown 
at 37°C in a humidified atmosphere containing 5% CO2. 
2.2. Reagents 
For siRNA transfections, we used DharmaFECT 1 (DF) transfection reagent and siRNA duplexes acquired 
from Dharmacon (Thermo Fisher Scientific, USA). In the screen and the follow-up experiments, 
siGENOME non-targeting control pool#2 and the PLK1 SMARTpool siRNA were used as negative and 
positive control, respectively. For flow cytometry, immunoblotting and colony formation experiments, REV3 
expression was silenced with ON-TARGETplus SMART pool REV3L (siREV3), while ON-TARGETplus 
non-targeting pool (siNT) was used as a negative control and buffer only treatment (buffer) was used to 
determine the effect of the transfection reagent. 
Hydroxyurea (HU) was acquired from Applichem, Germany. CellTiter-Blue® Cell Viability Assay reagent 
was purchased from Promega, USA. 
Oligonucleotides used for cloning and primers for rtPCR were ordered from Microsynth, Switzerland. 
Sequences of the rtPCR primers for REV3 and Histone H3 mRNA were disclosed previously (Knobel et 
al., 2011). The following primers were used for detection of RRM1 mRNA levels by qPCR: forward 5’- 
CCTGGGAACCATCAAATGCAGCAA-3’ and reverse 5’- GGGCCAGGGAAGCCAAATTACAAA-3’. 
2.3. Vector cloning and transfection 
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shREV3-4 and shSCR were introduced previously (Knobel et al., 2011). The short hairpin RRM1 oligos: 
5’-GATCCCCGCACAGAAATAGTGGAGTATTCAAGAGATACTCCACTATTTCTGTGCTTTTTA-3’ and 5’-
AGCTTAAAAAGCACAGAAATAGTGGAGTATCTCTTGAATACTCCACTATTTCTGTGCGGG-3’ were 
annealed and ligated into pSuperior.puro as described by the manufacturer (OligoEngine, Seattle, WA). 
The shRNA and H1 promoter fragments were subsequently transferred into the constitutive expressing 
lentiviral vector pLVTHM (Addgene, Cambridge, MA). Replication-deficient lentiviral particles were 
produced and titrated as described previously (Knobel et al., 2011) 
2.4. Lentiviral transduction and colony formation assay 
Lentiviral transduction and subsequent colony formation assay were performed as described previously 
(Knobel et al., 2011). For combined siRNA transfection, lentiviral transduction and subsequent colony 
formation, the procedure was as follows; 25,000 cells per well were seeded in 6-well plates and 
transfected 24 hours later with 50 nM siRNA (targeting REV3 or non-targeting control) using 80-times 
diluted DF. The medium was exchanged 24 hours after transfection. Another 24 hours later, cells were 
trypsinized, counted and 500 cells per well were seeded in 6-well plates for shRRM1 lentiviral transduction 
and colony formation assay, which was performed as described previously (Knobel et al., 2011). 
2.5. Genome-wide siRNA screening and follow –up experiments 
High-throughput screening (HTS) was done essentially as described previously (Siebring-van Olst et al., 
2013). One day before siRNA transfection, S1C6 or R1B6 cells (750 cells per well) were seeded in 272 
transparent flat-bottom 96-well plates (TPP, Switzerland) in 80 µl of complete culture medium. The next 
day, 10 µl of DF diluted 250-fold in DMEM was dispensed into 384-well siRNA library plates comprising 
the siARRAY human genome library and negative and positive control siRNAs at 2.5 pmol in 10 µl siRNA 
buffer (Dharmacon) prepared in advance. The resulting 20 µl transfection mixes were transferred to the 
cell culture plates, resulting in a final siRNA concentration of 25 nM. After transfection, cells were grown 
for 5 days before adding 20 µl per well CellTiter-Blue Reagent. The plates were incubated for 4 hours at 
37°C following which 50 µl of 3% SDS solution was added to stop the reaction. Fluorescence was 
measured at 540 nm excitation and 590 nm emission wavelengths. 
For the deconvolution of the siRNA pools, the experimental conditions were identical, i.e. 25 nM of siRNA 
and 0.04 µl of DF per well in 96-well plates. For double transfections, 25 nM of each siRNA and 0.08 µl of 
DF were used. 
2.6. Data and statistical analysis 
For reading, pre-processing and normalization of the raw fluorescence data, the cellHTS2 Bioconductor 
package was employed (Boutros et al., 2006). The data were per plate normalized to the negative control 
and log-transformed. To generate the differential viability list, genes were sorted by the absolute difference 
of the mean viability scores for the two cell lines, each screened in two independent screens. Bayesian 
statistics for linear models in limma package (Smyth, 2004) was used to calculate the P-value for each 
gene. For gene set enrichment analysis we employed ROMER from limma (Majewski et al., 2010). 
To assess statistical significance of treatment effects (siREV3, shREV3, shRRM1 and HU) and their 
interactions, two-way Analysis of Variance (ANOVA) was performed. The effect of siRNA transfection was 
inferred from the comparison of buffer only and siNT treated samples. To isolate the effects associated 
with silencing REV3 expression (iREV3) from the total effect of siREV3 transfection (siREV3) we 
presented the latter as a combination of pure silencing (iREV3) and other transfection effects that can be 
estimated from the effects of control non-targeting siRNA transfection (siNT). Both REV3 silencing 
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(iREV3) and control siRNA transfection (siNT) effects were assigned to the samples subjected to siREV3 
transfection, thereby allowing estimation of the pure effect of REV3 silencing (iREV3). Following 
established methodology (Slinker, 1998), p-values of ANOVA interaction effects (e.g. HU:iREV3) were 
used as criteria for the statistical significance of treatments synergy. For pairwise comparisons, two-tailed 
Student’s t test was employed. 
2.7. Flow cytometry 
For flow cytometry 25,000 cells per well were seeded in 6-well plates and transfected as described above 
(50 nM siRNA and 80-fold diluted DF). 24 hours after transfection, the medium was exchanged and 
another 24 hours later, cells were treated with 0.25 µM HU. After 24 hours, cells were labeled with 10 μM 
5-ethynyl-2′-deoxyuridine (EdU) for 60 min (according to the manufacturer’s instructions (C35002; 
Invitrogen)), harvested by trypsinization, and fixed for 20 min with ice-cold 70% Ethanol at room 
temperature. Cells were washed with 1% BSA/PBS, pH 7.4, permeabilized with 0.5% saponin/1% 
BSA/PBS for 10 minutes, and stained in the fixation buffer with anti–γH2AX antibody (05-636, EMD 
Millipore) or anti-RPA32/RPA2 antibody (ab2175, Abcam) overnight at 4°C, followed by incubation with a 
secondary antibody (a31553, Invitrogen) for 30 min at room temperature. Subsequently, cells were treated 
with 20ug/ml RNase A and DNA was stained with 0.5 μg/ml propidium iodide (Sigma-Aldrich). Cell 
fluorescence was measured on an Attune flow cytometer (Applied Biosystems) and analyzed with the 
Attune cytometric software v1.2.5 (Applied Biosystems). Buffer treated controls were used to set the 
gating threshold for γH2AX (and RPA) to 1% as described before (Kataoka et al., 2006). 
2.8. Immunoblotting 
Immunoblotting was performed essentially as described earlier (Knobel et al., 2011). The following primary 
antibodies were used: ATM-pS1981 (Epitomics, 2152-1, 1:1000), ATM (GeneTex GTX70103, 1:1000 ), 
Chk1-pS345 (Cell Signaling, 2348, 1:1000), Chk1 (Santa Cruz, sc-8408, 1:100). 
3. Results 
3.1. Generation and characterization of an isogenic pair of cell lines for REV3 synthetic 
sickness/lethality (SSL) screening 
In order to define synthetic lethal gene interactions with REV3, we generated A549 NSCLC cell lines 
expressing short hairpin RNAs targeting REV3 and control cell lines expressing a shRNA with scrambled 
sequence. Multiple independent clones were made and tested. Translesion synthesis is a major pathway 
involved in bypass and repair of DNA crosslinks and it is known that reduction of REV3 levels is 
associated with increased sensitivity to DNA crosslinking agents (Enoiu et al., 2012; Hicks et al., 
2010).Therefore, we based selection of the most suitable cell lines for screening on their REV3 expression 
levels and their cisplatin sensitivity as a functional readout.Two cell lines R1B6 and S1C6, ,expressing 
REV3 shRNA and a scrambled shRNA respectively, were selected for use in HTS. Compared to the 
parental cell line A549, the REV3 mRNA expression level in S1C6 cells was identical, whereas REV3 
expression in R1B6 cells was decreased to 49% (Fig.1A). The cisplatin sensitivity assessed by 
quantitation of cell viability 5 days after continuous drug treatment, differed significantly for the two cell 
lines. The REV3 deficient cell line R1B6 was up to 2.7 times more sensitive than its proficient counterpart 
S1C6 (43% versus 16% at 3 µM, t-test p<0.01; Fig. 1B), indicating that the decrease of REV3 mRNA 
expression in R1B6 cells has functional consequence. 
3.2. Genome-wide siRNA screening for REV3 SSL interactions 
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First, we optimized the HTS setup, with respect to number of seeded cells per well, suitable conditions for 
automated forward siRNA transfection and incubation time after transfection before assessing cell viability. 
The optimized transfection conditions resulted in efficient gene knockdown (Fig. A. 1) and were used for 
primary HTS and secondary confirmation experiments. 
Next, whole human genome siRNA library screens were carried out with the pair of REV3 knockdown and 
control cell lines and cell viability as readout (Fig. 2). In detail, R1B6 or S1C6 cells were seeded in 96-well 
plates and transfected with the arrayed library comprising pooled siRNAs (4 siRNA per gene) targeting 
more than 20,000 human transcripts. The number of viable cells was assessed using CellTiter-Blue Cell 
Viability Assay and resulting values were normalized to non-targeting siRNA (siNT) controls included on 
every plate, log-transformed and scored. Both cell lines were screened twice. The screens showed high 
correlation between replicates, i.e. Pearson correlation coefficients between replicates was 0.87 for S1C6 
and 0.84 for R1B6 (Table A. 1). Assay quality metrics were excellent, with Z’ factors (Zhang et al., 1999) 
for positive (siPLK1) versus negative (siNT) controls generally exceeding 0.5. To identify genes whose 
silencing induced SSL specifically in REV3–deficient cells, the gene list with the corresponding values of 
viability was sorted by the absolute difference of the mean viability robust scores between S1C6 and 
R1B6 (Dataset B. 1). Genes were considered as primary hits when satisfied one of the following criteria: a 
differential viability score > 2.0 and p<0.05 (genes with the strongest differential effect, Table 1) or p<5e-4 
and differential viability score > 0.8 (high confidence genes, Table 2). Table 1 gives the 9 genes that were 
selected this way and two additional genes - UBE2N and RRM2. UBE2N, which ranked 30 in the screen, 
was included in the Table 1 and the further analysis based on its known connection to TLS. UBE2N is the 
human homologue of UBC13 that is required for PCNA polyubiquitination promoting REV3-independent 
post-replication DNA repair in yeast (Ball et al., 2009). 
Subsequently, selected primary screen hits were stratified by performing confirmation screens using S1C6 
and R1B6 cells and the parental A549 lung cancer cells. First, we performed a secondary confirmation 
screen testing the siRNA pools used in the primary screens (Fig. 3A). Positive control siPLK1 included in 
this experiment exhibited a similar killing effect on the three cell lines, with residual viability in the range of 
10-15%, indicating that transfection and knockdown was effective in all three cell lines. The REV3-
deficient cell line R1B6 was more sensitive to silencing of the tested genes than the two control cell lines, 
confirming the validity of the results obtained by the high throughput screen. Next, we retested some of 
the genes by separately transfecting the 4 individual siRNAs targeting these genes. Fig. A. 2 represents 
the data for 10 selected genes (RRM1, LMTK3, CACNA1A, COPZ1, TXN, A1BG, KPNB1, CFLAR, 
GPR27 and UBE2N) that showed a synthetic lethal/proliferation defect phenotype with REV3 silencing in 
A549 NSCLC cells, confirmed in multiple independent experiments using 2 or more different siRNAs.  
Silencing of RRM1, the large subunit of ribonucleotide reductase (RNR), showed the second strongest 
differential effect in the primary screen and a very robust profile in the deconvolution analysis, i.e. all four 
tested siRNAs had a more pronounced cytotoxic effect on REV3-deficient cells (Fig. A. 2). To validate this 
finding, and to exclude that the observed SSL was due to a clonal effect in R1B6 cells, we silenced REV3 
with siRNA and RRM1 using a lentiviral vector expressing a short hairpin RNA (LV-shRRM1) in the 
parental A549 cells. Cell survival and proliferation capacity was measured by colony formation assay. Fig. 
3B shows that siREV3 transfection in combination with lentiviral RRM1 silencing synergistically reduced 
colony formation (ANOVA, siREV3:LVshRRM1 p=0.024, Table A. 2). 
3.3. Silencing REV3 in combination with inhibition of nucleotide synthesis synergistically 
reduces cancer cell growth. 
RRM1 encodes the large subunit of ribonucleotide reductase (RNR). Notably, silencing of the small 
subunit of RNR, RRM2, also scored in the top 2% (rank 292). This suggests that inhibition of the catalytic 
function of RNR, rather than a subunit-specific effect, is involved in the observed reduction of the number 
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of cells in a REV3-deficient background. To corroborate this, we investigated if we could reproduce the 
REV3 SSL with a drug that inhibits RNR catalytic activity. Hydroxyurea (HU) is a drug used in the 
treatment of myeloproliferative disorders that inhibits RNR by scavenging tyrosyl free radicals of the small 
subunit required for reduction of ribonucleotides to deoxyribonucleotides. We performed colony formation 
assays after lentiviral transduction (with LV-shSCR or LV-shREV3) followed by continuous HU treatment 
(Fig. 4). To account for the effect of lentiviral transduction we included it in the ANOVA model for both LV-
shSCR and LV-shREV3 transduced samples allowing calculation of the pure REV3 silencing effect 
(iREV3). While the colony formation was reduced by REV3 silencing alone (p=2.3e-13), its combination 
with HU treatment caused a more pronounced decrease in the number of cells than could be expected by 
mere superposition of the individual effects, the interaction effect (HU:iREV3) being statistically significant 
(ANOVA, p=0.018, Table A. 2). 
RNR is a critical enzyme in de novo nucleotide synthesis. To assess whether alterations in nucleotide 
synthesis pathways in general are synergistic with REV3 silencing, we employed gene set enrichment 
analysis for linear models using rotation tests (ROMER) (Majewski et al., 2010), which is particularly 
suitable for the analysis of experiments with a small number of replicates (Dorum et al., 2009). We tested 
a set of KEGG pathways related to nucleotide metabolism (Table A. 3) and found that both purine and 
pyrimidine metabolisms were significantly enriched among the synthetic lethal genes (p-values 0.0041 and 
<1E-5, respectively). Since inhibition of RNR reduces the concentration of deoxyribonucleotides and leads 
to induction of replication stress (Feng et al., 2011), we tested whether the reduction in viability upon 
silencing of REV3 in combination with RNR inhibition can be extended to genes associated with 
replication stress. To guarantee an unbiased analysis, we generated a gene set by search of the NCBI 
human gene database with the term “replication stress” (Table A. 4). The replication stress gene set was 
also significantly enriched among the genes that had a high differential score in the screen (p=0.00034). 
3.4. Down-regulation of REV3 expression enhances ssDNA formation induced by inhibition of 
ribonucleotide reductase 
The SSL interaction of REV3-depletion with inhibition of the catalytic function of RNR and with silencing of 
genes associated with replication stress led us to hypothesize that REV3 might be involved in coping with 
nucleotide deprivation-induced replication stress in cancer cells. To test this hypothesis, we performed a 
series of flow cytometry experiments to investigate DNA synthesis, cell cycle distribution, DNA damage 
response and replication stress in A549 cells after REV3 silencing and HU treatment. The gating strategy 
for the flow cytometry experiments is illustrated in Fig. A. 3. 
HU treatment inhibited DNA synthesis, as evidenced by a reduced median EdU incorporation (Fig. 5A). 
Silencing of REV3 significantly enhanced DNA synthesis inhibition by HU (siREV3 transfection and HU 
treatment compared to siNT transfection and HU treatment; t-test p<0.05). RPA2 is a subunit of replication 
protein A (RPA), a protein that binds single-stranded DNA (ssDNA). Detection of chromatin-bound RPA 
can be used to track the increase in cellular ssDNA (Forment et al., 2012), a characteristic feature of 
replication stress (Vassin et al., 2009). Down-regulation of REV3 expression did not change significantly 
the fraction of RPA2-positive cells, compared to siNT control transfection (Fig. 5B). In contrast, HU 
treatment significantly increased the number of RPA2-positive cells. Both control and REV3 siRNA 
transfections augmented the increase in ssDNA in response to HU, but this effect was stronger upon 
REV3 silencing. The synergy between HU treatment and REV3 silencing was significant evidenced by the 
p-value for the interaction effect HU:iREV3 (ANOVA, p=0.048, Table A. 2). An increased RPA2 signal can 
not only be due to enhanced replication stress but also to increased DNA end-resection during the 
process of DSB repair. To differentiate between these two possible causes we investigated whether the 
observed increase in RPA staining was accompanied by changes in DNA damage response. 
Phosphorylated histone H2AX (γH2AX) is a marker for the cellular response to various types of DNA 
damage including DSBs (Marti et al., 2006). HU treatment was associated with a moderate but significant 
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increase in the fraction of γH2AX positive cells (Fig 5C). Unexpectedly, siNT transfection increased 
γH2AX induction by HU treatment (ANOVA, HU:siNT p=0.016, Table A. 2), whereas siREV3 transfection 
did not lead to a significant change compared to HU-only treated cells (t-test, HU vs HU+siREV3 NS). 
Interestingly, comparison of siNT+HU and siREV3+HU revealed a significant decrease of H2AX 
phosphorylation after REV3 silencing and subsequent HU treatment (ANOVA, HU:iREV3 p=8.8e-4, Table 
A. 2). Hence, REV3 silencing did not promote DSB induction in response to HU treatment. In fact, it 
seemed to inhibit HU-induced DNA damage accumulation as demonstrated by decreased H2AX 
phosphorylation. Nevertheless, this observation has to be interpreted with a certain caution due to the 
strong effect of the control transfection. 
To further investigate in more detail the role of REV3 in counteracting replication stress, we analyzed the 
cell cycle distribution after inhibition of REV3 expression and HU treatment (Fig. 6 A-C). In the absence of 
HU treatment, REV3 silencing significantly decreased the fraction of cells in S-phase, whereas the fraction 
of cells in the G2-phase of the cell cycle was significantly increased, confirming an earlier observation 
(Knobel et al., 2011). This is in agreement with a suggested function of REV3 outside of S-phase 
(Brondello et al., 2008). As expected, HU treatment induced a pronounced S-phase accumulation. This 
accumulation was not further enhanced by additional REV3 silencing, but notably also REV3-specific S-
phase depletion was not detected. Combination of HU treatment and REV3 silencing lead to a significant 
synergistic increase in S- and decrease in G2 cell fractions (ANOVA, HU:iREV3 p=0.0062 and 3.9e-5 
respectively, Table A. 2) reflecting that HU treatment perturbed the cell cycle distribution of REV3-deficient 
cells more than that of controls. Thus, the increase in the fraction of S-phase cells induced by HU 
treatment was more pronounced in REV3-deficient compared to REV3-proficient cells suggesting an 
increased role of REV3 in S-phase cells upon HU treatment. We observed that the fraction of sub-G1 cells 
did not change upon HU treatment alone (3.5±0.4%, P=0.54) and combined REV3 silencing and HU 
treatment (3.3±1.4%, P=0.50) compared to control (4.2±1.7%) implying that observed synergy is rather 
due to proliferation defect than induction of apoptosis. We also compared the fractions of RPA positive 
cells in different cell cycle phases (Fig.6 D-F). The S-phase fraction of siREV3+HU treated cells contained 
a significantly larger proportion of RPA positive cells than the S-phase fractions of siNT+HU or HU treated 
cells (t-test, p<0.05). Such a difference was not observed in G1- and G2-phases. This indicates that the 
synergistic increase in cellular ssDNA upon combined siREV3 transfection and HU treatment (see Fig. 5) 
occurs mainly in the S-phase of the cell cycle. This is consistent with the role of polδ in DNA replication 
upon RS. 
3.5. REV3 silencing enhances RS signaling 
To investigate whether increased H2AX phosphorylation is due to RS-induced DSB formation, we 
performed immunoblotting analysis of ATM phosphorylation. ATM phosphorylation at serine 1981 is a 
specific marker for DSBs (So et al., 2009). In addition, CHK1 is phosphorylated by ATR in response to 
replication fork stalling and was used to assess the quantity of stalled but not resolved or collapsed 
replication forks. HU treatment solely induced CHK1 phosphorylation whereas ionizing radiation, as a 
positive control for DSBs, mainly induced ATM phosphorylation (Fig. 7). Treatment with 2 mM HU for 80 
minutes resulted in phosphorylation of both CHK1 and ATM. Immunoblotting analysis revealed that the 
response to HU treatment was affected by both preceding siNT and siREV3 transfections. In detail, 
preceding control transfection increased HU-induced p-ATM and decreased p-CHK1, which might be 
attributable to collapsed replication forks due to the increased effective HU concentration upon 
transfection, as discussed below. In comparison, HU treatment after siREV3 transfection leads only to a 
modest increase in ATM phosphorylation but further enhances CHK1 phosphorylation, which might 
indicate accumulation of stalled but intact replication forks.  
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4. Discussion 
This study aimed to identify SSL gene interactions with REV3 in lung cancer cells. For screening, we used 
stable cell lines obtained from A549 NSCLC cells carrying a plasmid vector expressing a short hairpin 
against REV3 or a scrambled control shRNA. The approximately 50% decrease in REV3 mRNA 
expression in the cell line R1B6 is of physiological relevance since it conferred cisplatin sensitivity.  
Screening with a whole human genome siRNA library allowed us to determine synthetic lethal interactions 
with REV3 in an unbiased way. Statistically significant hits were ranked according to their differential 
inhibition of cell viability in the pair of cell lines. Consequently, a top position of a gene in the primary hit 
list indicates that the proliferation of the NSCLC cells is heavily dependent on this gene in a REV3-
deficiency dependent manner. Our analysis revealed that silencing of RRM1, the large subunit of RNR, 
had the second most pronounced effect in reduction of cell viability specifically in a REV3-deficient 
background. Additionally, RRM2, the small subunit of RNR, also ranked among the top 2% genes in our 
screen, further corroborating that inhibition of RNR is synthetic lethal with REV3 depletion. RRM2 is 
overexpressed in many tumor types. For example, it was shown that RRM2 is highly (~15x) 
overexpressed in NSCLC (Hou et al., 2010). Moreover, RRM2 was suggested to act in cooperation with a 
variety of oncogenes to increase their transformation and tumorigenic potential (Fan et al., 1998). It is well 
known that inhibition of RNR function affects proliferation of cancer cells to a greater extent than normal 
cells, which allows successful application of small molecule inhibitors targeting RNR in the clinic for cancer 
treatment (reviewed in (Cerqueira et al., 2005)). Together, these data suggest that cancer cells are 
frequently addicted to RNR overexpression. Therefore, we further focused our analysis on the synthetic 
lethal interaction of REV3 with RNR.  
Downregulation of RRM1 expression and treatment with HU, a drug inhibiting small subunit RRM2 of 
RNR, in combination with transient siRNA-based depletion of REV3 resulted in synergistic inhibition of cell 
proliferation (i.e. synthetic sickness or proliferation defect) as indicated by reduced EdU incorporation. 
This indicates that the observed effects are not RNR-subunit specific but rather related to RNR catalytic 
function. Inhibition of RNR catalytic activity leads to deprivation of deoxyribonucleotides, reduced 
replication rate and stalling of replication forks (Petermann et al., 2010). Higher concentrations of HU 
(~2mM) can induce complete cell cycle arrest, which is often exploited for synchronization of cultured 
cells. The concentrations that we used (0.2-0.3 mM) show very limited cytotoxicity and allow replication 
sufficient for colony formation experiments even upon long–term treatment (Fig. 3). In addition, the 
absence of a significant increase in sub-G1 cell fraction upon HU and HU+siREV3 treatments indicates 
that 24 hours treatment with these HU concentrations does not induce apoptosis. However these 
concentrations are sufficient to create nucleotide pool imbalance (Skog et al., 1992), thereby generating 
conditions of mild replication stress. Therefore, we tested whether RS-related genes were 
overrepresented among the genes whose silencing induced SSL in the REV3-deficient background and 
found this enrichment to be significant.  
We proceeded with detection of chromatin-bound RPA, an indicator for replication-associated ssDNA 
formation, and controlling levels of DNA damage measured by H2AX phosphorylation. Compared to 
individual treatments, combination of HU treatment with REV3 silencing synergistically increased the 
fraction of RPA positive cells, which was not accompanied by increased levels of γH2AX. Thus, under 
conditions of HU-induced RS, silencing of REV3 in the lung cancer cell line A549 impairs DNA replication 
but does not lead to increased DNA damage accumulation, indicating that polδ is directly involved in DNA 
replication. This is further corroborated by our finding that the fraction of S-phase cells after siREV3+HU 
treatment is significantly higher than could be expected from a simple additive effect of HU treatment and 
REV3 silencing, which suggests an important role of REV3 in the DNA synthesis of HU-treated cells. 
Moreover, the significant increase in RPA positive cells upon combined HU treatment and REV3 silencing 
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(HU+siREV3 vs HU+siNT) was found only in S phase and not in G1 and G2 phases of the cell cycle, 
whereas both G2 and S phases would be affected if homologous recombination was involved. 
We did not expect that the concentrations of HU that we used would strongly induce DNA damage since 
treatment of human cancer cells with 8 times higher HU concentration for the same time (24 hours) 
resulted only in a moderate induction of DSBs as shown by pulse-field gel electrophoresis (Petermann et 
al., 2010). Also single stranded breaks were not detected by alkaline unwinding technique (Skog et al., 
1992) after treatment with a comparably low concentration of HU (0.1 mM). Nevertheless, due to the high 
sensitivity of the flow cytometry method, we detected increased H2AX phosphorylation upon HU treatment 
that was further increased by preceding transfection with control siRNA. Lipid-mediated siRNA 
transfection is known to affect permeability of the cell membrane. In analogy, we speculate that the 
increased γH2AX and RPA2 signals detectable after control transfection and subsequent HU treatment 
might be explained by the increased drug penetration and therefore a higher effective intracellular HU 
concentration even when cells were treated after removal of the transfection reagent.  
It was previously reported that DNA damage induced H2AX phosphorylation is replication dependent and 
can be reduced by contact inhibition (Marti et al., 2006). Our analysis of EdU incorporation revealed that 
HU treatment significantly reduced the fraction of replicating cells in REV3-deficient cells compared to 
REV3-proficient cells. Thus, we speculate that the reduced level of γH2AX (by flow cytometry) and the 
diminished ATM phosphorylation (by immunoblotting analysis) in siREV3+HU treated cells compared to 
siNT+HU control cells might be attributed to the decreased DNA replication rate upon REV3 silencing and 
subsequent reduction of HU-induced replication fork breakage. Similarly, replication slowdown upon REV3 
silencing and subsequent HU treatment might also explain the reduced rate of replication-associated fork 
collapse., However, due to strong influence of siNT transfection on cells, these data should be regarded 
as inconclusive. Consequently, it is a matter of further investigations to elucidate in more detail whether 
REV3 silencing inhibits replication fork collapse upon RS. 
Nucleotide concentrations are tightly regulated throughout the cell cycle and perturbation of this regulation 
leads to increased mutation rate (Kumar et al., 2011). One of the key components of this regulation is the 
regulation of RNR activity. In yeast, upregulation of RNR activity increases replication fork speed, 
indicating that nucleotide pools are limiting for normal DNA replication (Poli et al., 2012). Both in yeast and 
mammalian cells, nucleotide pools are expanded upon entry in the S-phase. In mammalian cells, exit from 
S phase is associated with a decrease of dNTP pools, most notably of dCTP changing 3-fold (Leeds et al., 
1985; Skoog et al., 1973). The absolute changes of nuclear nucleotide pools during the cell cycle are even 
more pronounced (Bjursell and Skoog, 1980) perhaps making them limiting for late DNA replication. Thus, 
in addition to the role of Polδ in replication after HU-generated nucleotide deprivation, we speculate that 
Polδ might also be involved in the late DNA replication. In this context, the recently discovered role of Polδ 
in the stability of fragile sites (Bhat et al., 2013) can be viewed as a particular case of late DNA replication, 
since fragile sites are known to be replicated late during the cell cycle and their stability is compromised by 
RS inducing agents (aphidicolin, hydroxyurea, low folate medium). In detail, common fragile sites (CFS) 
are replicated in late S phase and their replication is even further delayed by aphidicolin, causing the 
replication of CFS to persist in G2 phase (Le Beau et al., 1998). In our study, upon REV3 silencing in the 
absence of HU treatment, an increase in the fraction of cells in the G2-phase was the most prominent 
effect (1.5 fold), suggesting that REV3 plays its most important role in this cell cycle phase, which is in 
agreement with the recently reported enrichment of REV3 on the chromatin in G2/M and its role in fragile 
site maintenance (Bhat et al., 2013). However, HU treatment increased the S-phase fraction of REV3 
depleted cells more than that of cells without REV3 silencing, which suggests that REV3 has increased 
importance in S-phase upon HU treatment. Thus, we speculate that under our experimental conditions, 
the HU treatment induces in A549 cells the early onset of the “late DNA replication”, which typically occurs 
during G2-phase, already in S-phase by creating conditions of nucleotide shortage. In other words, REV3 
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function in replication does not seem to be confined to a certain cell cycle phase but it rather becomes 
important whenever replication problems are encountered. 
Late replicating DNA regions were previously shown to be particularly prone to mutagenesis in both yeast 
(Agier and Fischer, 2012) and humans (Stamatoyannopoulos et al., 2009), indicating a likely conservation 
of the mechanism underlying this phenomenon. In yeast, comparison of available catalytic Km parameters 
of polymerases δ, δ and ε (Table A. 5) suggests that in the conditions of nucleotide shortage (dN<<Km) 
Polδ can bind nucleotides with the highest affinity, because its Km values for incorporation of 3 nucleotides 
are 5-20 times lower than those of Polδ. This is due to Polδ lysine residue K1061 that binds the 
triphosphate group of nucleotides, increasing the binding affinity, but decreasing replication fidelity (Howell 
et al., 2008; Zhong et al., 2006). This error-prone nature of Polδ suggests that it can contribute to the late 
replication mutagenesis by participating in this process as suggested above. 
Nucleotide biosynthesis is commonly upregulated in cancer cells to cope with their increased metabolic 
requirements (Tong et al., 2009). Therefore, many oncogenes not only induce replication stress (Gorgoulis 
et al., 2005) (Halazonetis et al., 2008; Neelsen et al., 2013), but also activate nucleotide synthesis (Bester 
et al., 2011). Consequently, concentrations of the 4 dNTPs in tumor cells are on average 6-11 fold higher 
than in normal cells (Traut, 1994). But, if a cancer cell fails to adjust its metabolism, nucleotide deficiency 
promotes genomic instability (Bester et al., 2011) and also can lead to oncogene-induced senescence 
(Aird et al., 2013). Interestingly, cells lacking REV3 undergo senescence and accumulate persistent DNA 
DSBs at later time points (Knobel et al., 2011; Lange et al., 2013), possibly reflecting their inability to cope 
with RS (Feng et al., 2011). Based on our present findings it is tempting to hypothesize that oncogene-
induced RS could be the unifying feature responsible for the observed cancer cell specific growth arrest 
upon REV3 silencing described earlier by our group (Knobel et al., 2011). 
The function of Polδ in DNA replication under conditions of nucleotide deficiency-associated replication 
stress might also help in understanding its role in embryogenesis. Rev3 knockout is embryonic lethal in 
mice causing depletion of the hematopoietic compartment and embryonic stem cells (Esposito et al., 
2000). A recent study showed that hematopoietic tissue is highly prone to RS associated with nucleotide 
pool imbalance (Austin et al., 2012). Besides, human embryonic stem cells are very sensitive to RS 
(Desmarais et al., 2012) and high levels of RS are observed upon stem cell induction (Pasi et al., 2011). 
Apparently, hematopoietic and embryonic stem cells overexpress REV3 in order to cope with excessive 
RS and suffer the most from REV3 depletion. 
In summary, our study identifies a novel function of human polδ in coping with replication stress thereby 
broadening our understanding of its role in cell biology. 
Appendices A and B. Supplementary material 
Supplementary figures and tables (Appendix A) and Dataset B. 1 (Appendix B) are available online, 
including Supplementary References (Dieckman et al., 2010; Haracska et al., 2001; Johnson et al., 2003; 
Washington et al., 1999). 
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Tables 
Rank Gene P-value 
Viability 
difference 
score 
Gene name 
1 GPR27 1.7E-03 2.67 G protein-coupled receptor 27 
2 RRM1 1.6E-02 2.49 ribonucleotide reductase M1 
3 CFLAR 4.9E-05 2.24 CASP8 and FADD-like apoptosis regulator 
4 LMTK3 1.2E-02 2.19 lemur tyrosine kinase 3 
5 CCR6 4.6E-04 2.13 chemokine (C-C motif) receptor 6 
7 CACNA1A 2.3E-03 2.10 calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 
8 COPZ1 9.4E-03 2.09 coatomer protein complex, subunit zeta 1 
9 CDY1 2.4E-02 2.09 chromodomain protein, Y-linked, 1   
10 CSAD 2.2E-02 2.08 cysteine sulfinic acid decarboxylase   
… … … … … 
30 UBE2N 8.4E-04 1.63 ubiquitin-conjugating enzyme E2N (UBC13 homolog) 
292 RRM2 4.9E-03 0.85 ribonucleotide reductase M2 
Table 1. Highest ranking genes with a stronger effect on viability of REV3-deficient cells compared to 
control cells. All the genes in the screen were scored based on the normalized viability of the cells after 
silencing. Genes are ranked according to the difference of scores for control and REV3-deficient cell lines. 
A filter of P<0.05 is applied to exclude low-confidence genes. Results are from four whole-genome RNAi 
screens (two on each cell line) as described in the material and methods section. The genes with the 
viability difference score greater than 2 are given in the table. Additionally, UBE2N and RRM2 are 
included (see details in the text). 
Rank Gene P-value 
Viability 
difference 
score 
Gene name 
1 TXN 2.8E-05 1.50 thioredoxin 
2 CFLAR 4.9E-05 2.24 CASP8 and FADD-like apoptosis regulator 
3 ATAD1 5.1E-05 0.88 ATPase family, AAA domain containing 1 
4 A1BG 9.9E-05 1.83 alpha-1-B glycoprotein 
5 SLC16A10 1.7E-04 1.24 solute carrier family 16 (aromatic amino acid transporter), member 10 
6 FAM107A 2.1E-04 0.82 family with sequence similarity 107, member A 
9 RFXAP 3.3E-04 0.84 regulatory factor X-associated protein 
14 CCR6 4.5E-04 2.13 chemokine (C-C motif) receptor 6 
Table 2. Highest ranking genes with the lowest P-values for the effect on viability of REV3-deficient cells 
compared to control cells. Genes are ranked according to the P-values of the score differences for control 
and REV3-deficient cell lines. Only genes with P-values lower than 5E-4 and viability difference score 
greater than 0.8 are included. 
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FIGURE CAPTIONS 
Figure 1. Characterization of the cell lines used in synthetic sickness/lethality screens. (A) REV3 
mRNA level determined by rtPCR in the parental cell line A549, clone R1B6 carrying a short-hairpin 
RNA targeting REV3 mRNA and the control cell line S1C6 carrying a scrambled control construct. ** P 
<.01. Shown are means ± standard deviation (SD), n=3. (B) Sensitivity of the generated cell lines to 
continuous cisplatin (CDDP) treatment. Cell viability was determined after 5 days of CDDP treatment. 
Shown are means ± SD, n=3. 
Figure 2. Schematic representation of the screening procedure. 24 hours after plating, cells are 
transfected with siRNA from the Dharmacon siARRAY human genome library targeting >20,000 
transcripts. Cells are incubated for 5 days and CellTiter Blue viability assay is used to assess the 
number of viable cells in every well. Fluorescent signal is normalized and compared between the two 
cell lines – S1C6 with normal and R1B6 with reduced REV3 expression – to find the genes whose 
silencing predominantly affects REV3-deficient cells. The dashed line represents the hit selection 
threshold applied to generate the hit list shown in Table 1 (viability difference score greater than 2). 
Figure 3. Inhibition of ribonucleotide reductase (RNR) expression selectively reduces number of 
REV3-deficient cancer cells. (A) Confirmation screen with siRNA pools targeting genes with high 
specificity for reducing cell growth of REV3 deficient cells, performed on A549, S1C6 and R1B6 cells. 
Data for 9 selected genes including PLK1 control are represented. Shown are means ± SD, n=3. (B) 
Quantitation of colony formation in A549 cell line after REV3 silencing by siRNA transfection and 
RMM1 silencing by transduction with a lentiviral vector carrying a short hairpin RNA (LV-shRRM1) at 
varying multiplicities of infection (MOI). Shown are means ± SD, n≥3. 
Figure 4. HU treatment and REV3 silencing have synergistic growth inhibitory effect on cancer cells. 
(A) Quantitation of the colony formation after REV3 silencing by LV-shREV3 and subsequent HU 
treatment. Shown are means ± SD, n≥3. (B) Image of a representative plate from a colony formation 
assay after REV3 silencing by LV-shREV3 and subsequent HU treatment. 
Figure 5. Effects of REV3 silencing and HU treatment on (A) EdU incorporation, (B) RPA2 and (C) 
γH2AX levels determined by flow cytometry . The cells were seeded and transfected the next day. 
After 24 hours, the medium was exchanged and after another 24 hours 0.25 mM HU was added. After 
24 hours of treatment, EdU was applied for 1 hour after which cells were harvested, fixed and stained. 
Shown are the standard box plots representing the median with interquartile range, n≥3. 
Figure 6. Effects of REV3 silencing and HU treatment on cell cycle distribution and RPA-positive cells. 
Panels show the percentages of cells in (A) G1, (B) S and (C) G2/M phase of the cell cycle; and the 
percentages RPA-positive cells in (D) G1, (E) S and (F) G2/M phase of the cell cycle. Shown are the 
standard box plots representing the median with interquartile range, n≥3. 
Figure 7. Combination of REV3 silencing with HU-treatment induces CHK1 activation that is not 
accompanied by ATM phosphorylation. A549 cells were transfected and 2 days later treated with 0.25 
mM HU for 24 hours. Cells treated with 2 mM HU for 80 minutes and cells irradiated with 5 Gy of γ-
radiation (IR) were used as controls. 
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Figure A. 1. s iR N A  s ilenc ing  resu lts  in  a  s trong decrease o f m R N A  leve ls  o f (A) R E V 3 and (B) R R M 1; 
48  hours  a fte r transfec tion , as  assessed by rtP C R . S how n are  m eans ± S D , n=3.  
Appendix A. Supplementary data 
Whole genome RNAi screens reveal a critical role of REV3 in coping 
with replication stress 
Ilya  N . K otov a, E llen  S iebring  - van O ls tb, P h ilip  A . K nobe la1, Ida  H . van der M eu len-M uilem an c, 
E m anue la  F e lle y-B osco a, V ic to r W . van B eusechem c, E gbert F . S m itb, R o lf A . S tahe la and T hom as M . 
M artia2* 
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C enter, 1081 H V  A m sterdam , the  N etherlands  
* C orrespond ing  au thor. C lin ic  o f T horac ic  S urgery, U n ivers ity H osp ita l B ern , 3010  B ern , S w itzerland . 
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Table A. 1. P earson ’s  corre la tion  va lues be tw een the  w ho le -genom e s ilenc ing  sc reens o f the  contro l 
(S 1C 6) and R E V 3-defic ien t (R 1B 6) ce ll lines . 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Fig.3. Colony formation 
 
Fig.4. Colony formation 
    Effect P 
 
Effect P 
    siNT 0.89172 
 
HU < 2.2e-16 *** 
   LVshRRM1 < 2.2e-16 *** iREV3 2.35E-13 *** 
   siREV3 1.98E-06 *** HU:iREV3 0.01848 * 
   siREV3:LVshRRM1 0.02423 * LVshSCR 0.95198 
    siNT:LVshRRM1 0.55105 
 
HU:LVshSCR 0.96875 
    
         Fig.5A. EdU incorporation 
 
Fig. 5B. RPA2 
 
Fig. 5C. γH2AX 
 Effect P 
 
Effect P 
 
Effect P 
 HU 1.46E-09 *** HU 1.93E-06 *** HU 4.97E-07 *** 
iREV3 0.0004234 *** iREV3 0.0055863 ** iREV3 0.0018778 ** 
HU:iREV3 0.221175 
 
HU:iREV3 0.048098 * HU:iREV3 0.0008756 *** 
siNT 0.0756801 . siNT 0.0007516 *** siNT 0.0078432 ** 
HU:siNT 0.4750325 
 
HU:siNT 0.0439644 * HU:siNT 0.0159109 * 
         Fig. 6A. G1-phase 
  
Fig. 6B. S-phase 
 
Fig. 6C. G2/M-phase 
 Effect P 
 
Effect P 
 
Effect P 
 HU < 2.2e-16 *** HU 3.60E-16 *** HU 0.554353 
 iREV3 0.0132 * iREV3 0.0013 ** iREV3 0.002 ** 
HU:iREV3 0.17327 
 
HU:iREV3 0.006225 ** HU:iREV3 3.92E-05 *** 
siNT 0.01997 * siNT 0.197753 
 
siNT 0.009057 ** 
HU:siNT 5.76E-05 *** HU:siNT 5.29E-05 *** HU:siNT 0.136432 
 
         Fig. 6D. RPA2 in G1-phase 
 
Fig. 6E. RPA2 in S-phase 
 
Fig. 6F. RPA2 in G2/M-phase 
Effect P 
 
Effect P 
 
Effect P 
 HU 0.04793 * HU 5.71E-05 *** HU 0.01371 * 
iREV3 0.42057 
 
iREV3 0.001676 ** iREV3 0.17857 
 HU:iREV3 0.81208 
 
HU:iREV3 0.187528 
 
HU:iREV3 0.79797 
 siNT 0.29564 
 
siNT 0.001701 ** siNT 0.15356 
 HU:siNT 0.66719 
 
HU:siNT 0.366021 
 
HU:siNT 0.65652 
 
Table A. 2. Results of two-way ANOVA of experimental data. Significance codes: *** P<0.001, ** P<0.01, 
* P<0.05. 
 
Gene set P-value 
Purine metabolism KEGG: hsa00230 0.0041 
Pyrimidine metabolism KEGG: hsa00240 <1E-5 
Replication stress [Homo sapiens]* 0.00034 
Table A. 3. Selected gene sets whose silencing had stronger effect on the viability of REV3-deficient cells. 
We tested whether nucleotide synthesis pathways and genes associated with replication stress are enriched 
among the genes whose silencing had stronger effect on the viability of REV3-deficient cells. The testing was 
performed by ROMER. *Replication stress gene list was generated by searching NCBI gene database with 
the term “replication+stress” (Table A. 4). 
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ID Gene Name 
7157 TP53 tumor protein p53 
1029 CDKN2A cyclin-dependent kinase inhibitor 2A 
4609 MYC v-myc myelocytomatosis viral oncogene homolog (avian) 
472 ATM ataxia telangiectasia mutated 
324 APC adenomatous polyposis coli 
3320 HSP90AA1 heat shock protein 90kDa alpha (cytosolic), class A member 1 
1111 CHEK1 checkpoint kinase 1 
545 ATR ataxia telangiectasia and Rad3 related 
983 CDK1 cyclin-dependent kinase 1 
2272 FHIT fragile histidine triad 
5591 PRKDC protein kinase, DNA-activated, catalytic polypeptide 
7486 WRN Werner syndrome, RecQ helicase-like 
898 CCNE1 cyclin E1 
641 BLM Bloom syndrome, RecQ helicase-like 
3014 H2AFX H2A histone family, member X 
1025 CDK9 cyclin-dependent kinase 9 
6117 RPA1 replication protein A1, 70kDa 
7158 TP53BP1 tumor protein p53 binding protein 1 
55294 FBXW7 F-box and WD repeat domain containing 7, E3 ubiquitin protein ligase 
2177 FANCD2 Fanconi anemia, complementation group D2 
83990 BRIP1 BRCA1 interacting protein C-terminal helicase 1 
7465 WEE1 WEE1 homolog (S. pombe) 
6118 RPA2 replication protein A2, 32kDa 
5976 UPF1 UPF1 regulator of nonsense transcripts homolog (yeast) 
11073 TOPBP1 topoisomerase (DNA) II binding protein 1 
64421 DCLRE1C DNA cross-link repair 1C 
5424 POLD1 polymerase (DNA directed), delta 1, catalytic subunit 
8317 CDC7 cell division cycle 7 
9025 RNF8 ring finger protein 8, E3 ubiquitin protein ligase 
571 BACH1 BTB and CNC homology 1, basic leucine zipper transcription factor 1 
79840 NHEJ1 nonhomologous end-joining factor 1 
5884 RAD17 RAD17 homolog (S. pombe) 
10769 PLK2 polo-like kinase 2 
64919 BCL11B B-cell CLL/lymphoma 11B (zinc finger protein) 
80198 MUS81 MUS81 endonuclease homolog (S. cerevisiae) 
25842 ASF1A ASF1 anti-silencing function 1 homolog A (S. cerevisiae) 
55723 ASF1B ASF1 anti-silencing function 1 homolog B (S. cerevisiae) 
10116 FEM1B fem-1 homolog b (C. elegans) 
8812 CCNK cyclin K 
79915 ATAD5 ATPase family, AAA domain containing 5 
80169 CTC1 CTS telomere maintenance complex component 1 
4796 TONSL tonsoku-like, DNA repair protein 
84893 FBXO18 F-box protein, helicase, 18 
79991 OBFC1 oligonucleotide/oligosaccharide-binding fold containing 1 
84083 ZRANB3 zinc finger, RAN-binding domain containing 3 
51550 CINP cyclin-dependent kinase 2 interacting protein 
92797 HELB helicase (DNA) B 
253714 MMS22L MMS22-like, DNA repair protein 
Table A. 4. Replication stress gene list, obtained by search of NCBI human gene database with the term 
“replication+stress”. 
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Figure A.2. D econvo lu tion  o f the  s iR N A  poo ls  w ith  the  h ighest d iffe ren tia l v iab ility scores  in  the  
screens. T he graphs show  the  ce ll surv iva l a fte r transfec tion  o f each o f 4  ind iv idua l s iR N A s. S how n 
are  m eans, n=3 . 
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Figure A. 3. G ating  s tra tegy fo r the  flow  cytom etry experim ents : (A) exc lus ion  o f debris , (B) exc lus ion  o f ce ll 
doup le ts , (C) γH 2A X  s ta in ing , sam e fo r R P A  (no t show n), (D) P I s ta in ing , (E) E dU  s ta in ing , (F) ce ll cyc le  
ana lys is . 
Polymerase 
Km values, µM 
dCTP-G dTTP-A dATP-T dGTP-C 
Yeast polζ 0.14 [1] - 0.39 [2] 0.11 [1] 
Yeast polδ 1.4 [3] 6.6 [3] 2.1 [3] 2.5 [3] 
Yeast polη 0.43 [4] 1.3 [4] 1.7 [4] 5.0 [4] 
 
Table A. 5. S teady-s ta te  k ine tic  param eters  K m  o f yeast po lym erases ζ , δ  and η . 
Supplemental References (Table A. 5) 
1. H aracska, L ., e t a l., Roles of yeast DNA polymerases delta and zeta and of Rev1 in the bypass of 
abasic sites. G enes D ev, 2001. 15(8 ): p . 945-54 . 
2 . Johnson, R .E ., e t a l., Yeast DNA polymerase zeta (zeta) is essential for error-free replication past 
thymine glycol. G enes D ev, 2003. 17(1 ): p . 77-87. 
3 . D ieckm an, L .M ., e t a l., Pre-steady state kinetic studies of the fidelity of nucleotide incorporation by 
yeast DNA polymerase delta. B iochem is try, 2010 . 49(34): p . 7344-50. 
4 . W ash ing ton , M .T ., e t a l., Fidelity and processivity of Saccharomyces cerevisiae DNA polymerase eta. 
J  B io l C hem , 1999. 274(52): p . 36835-8 . 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
 
 
Rank Accession LocusID gene t.stat p.value FDR differential viability
1 NM_018971 2850 GPR27 -9.40130222 0.00174188 0.48351905 2.666696
2 NM_001033 6240 RRM1 -4.58495536 0.01594019 0.57562388 2.494026
3 NM_003879 8837 CFLAR -28.272544 4.88E-05 0.36223643 2.239506
4 XM_055866 114783 LMTK3 -5.0885062 0.01171657 0.57562388 2.185977
5 NM_004367 1235 CCR6 -14.2674137 0.00045462 0.4422131 2.12946
6 NM_032432 84448 ABLIM2 -1.61260015 0.19731502 0.57687699 2.095655
7 NM_000068 773 CACNA1A -8.62504464 0.00229138 0.55038597 2.093034
8 NM_016057 22818 COPZ1 -5.47058773 0.00942725 0.57562388 2.089119
9 NM_004680 9085 CDY1 -3.95556876 0.0243616 0.57562388 2.077483
10 NM_015989 51380 CSAD -4.08080723 0.02230413 0.57562388 2.002543
11 NM_005825 10235 RASGRP2 -5.64643689 0.00856596 0.57562388 1.929405
12 NM_001235 871 SERPINH1 -4.28180354 0.01943851 0.57562388 1.911587
13 NM_003898 8871 SYNJ2 -5.40838033 0.00975832 0.57562388 1.903974
14 XM_114621 0 LOC203076 -5.68053476 0.00841076 0.57562388 1.884617
15 NM_004831 9441 CRSP7 -4.13362149 0.02150225 0.57562388 1.851575
16 NM_194295 196968 DKFZP434I1020- .96255391 0.05303191 0.57562388 1.844407
17 NM_198822 267020 ATP5L2 -3.45300726 0.03545878 0.57562388 1.826414
18 NM_130786 1 A1BG -22.8019329 9.87E-05 0.41872551 1.826085
19 NM_006575 11183 MAP4K5 -4.56275375 0.01616784 0.57562388 1.795191
20 NM_002476 4635 MYL4 -2.62773602 0.07139963 0.57562388 1.78976
21 NM_007372 11325 DDX42 -6.60219185 0.00530146 0.57562388 1.768141
22 NM_020860 57620 STIM2 -12.0041722 0.00079495 0.4422131 1.728933
23 NM_033118 85366 MYLK2 -10.0228782 0.00141959 0.48351905 1.727957
24 NM_002265 3837 KPNB1 -4.283361 0.01941818 0.57562388 1.689679
25 NM_023942 65999 MGC3036 -3.79144638 0.02743295 0.57562388 1.686953
26 NM_014781 9821 RB1CC1 -6.6442483 0.00519814 0.57562388 1.679061
27 NM_001898 1469 CST1 -2.52799019 0.07830432 0.57562388 1.67029
28 NM_014691 9716 AQR -2.3163166 0.09579444 0.57562388 1.633944
29 NM_001834 1212 CLTB -3.16229172 0.04480737 0.57562388 1.633539
30 NM_003348 7334 UBE2N -11.7996026 0.00084027 0.4422131 1.632375
31 NM_003278 7123 TNA -3.42053083 0.03637459 0.57562388 1.624359
32 XM_373466 0 LOC387690 -6.63472689 0.0052213 0.57562388 1.606136
33 NM_032561 84645 C22ORF23 -9.48055205 0.00169584 0.48351905 1.60546
34 XM_372048 0 LOC389672 -13.2410241 0.00057904 0.4422131 1.601918
35 NM_003301 7201 TRHR -4.69859912 0.01483652 0.57562388 1.591624
36 NM_006362 10482 NXF1 -1.94786259 0.13854814 0.57562388 1.574627
37 NM_014718 9746 CLSTN3 -3.10435482 0.04702074 0.57562388 1.573626
38 NM_175900 283897 FLJ35681 -4.93723055 0.01281745 0.57562388 1.573463
39 NM_002091 2922 GRP -2.51625887 0.07916805 0.57562388 1.571913
40 NM_014338 23761 PISD -4.12031145 0.02170087 0.57562388 1.569932
41 NM_012152 23566 EDG7 -8.52883436 0.00237437 0.55902722 1.556974
42 NM_001063 7018 TF -5.29569096 0.01039681 0.57562388 1.525556
43 NM_003806 8739 HRK -2.67089585 0.06864053 0.57562388 1.525383
44 NM_001776 953 ENTPD1 -11.1028897 0.0010222 0.48196901 1.517526
45 NM_020882 57642 KIAA1510 -4.8080603 0.01386363 0.57562388 1.515316
46 NM_000937 5430 POLR2A -4.91556246 0.01298575 0.57562388 1.515048
47 NM_021138 7186 TRAF2 -1.83262757 0.15618404 0.57562388 1.506787
48 NM_003329 7295 TXN -33.5783272 2.78E-05 0.36223643 1.502514
49 NM_018438 26270 FBXO6 -3.07077742 0.04836516 0.57562388 1.501946
50 NM_017986 55065 FLJ10060 -3.40139197 0.03692807 0.57562388 1.501052
51 NM_030651 80863 C6ORF31 -5.46438253 0.00945963 0.57562388 1.493475
52 NM_006421 10565 BIG1 -11.8308746 0.00083313 0.4422131 1.485841
53 NM_020861 57621 ZBTB2 -7.43644879 0.00365829 0.57562388 1.480462
Dataset B. 1. Results of the primary RNAi screens sorted by absolute difference of normalized viability scores between the control (S1C6) and REV3-deficient (R1B6) cell lines.
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54 NM_004462 2222 FDFT1 -5.83647831 0.00774513 0.57562388 1.470012
55 NM_001492 2657 GDF1 -2.63675476 0.07081219 0.57562388 1.46846
56 XM_290811 80816 KIAA1713 -5.74797719 0.00811424 0.57562388 1.44717
57 NM_002455 4580 MTX1 -1.72566142 0.17484922 0.57562388 1.431868
58 NM_001015 6205 RPS11 -2.70797113 0.06637267 0.57562388 1.420874
59 XM_016548 203611 CDY -2.8259668 0.05973521 0.57562388 1.420741
60 NM_000832 2902 GRIN1 -4.27150969 0.01957357 0.57562388 1.419661
61 NM_014207 921 CD5 -4.23608314 0.02004751 0.57562388 1.418187
62 NM_015470 26056 GAF1 -2.04238114 0.12576869 0.57562388 1.404183
63 NM_012318 3954 LETM1 -1.8765361 0.14917966 0.57562388 1.400908
64 NM_001318 1444 CSHL1 -3.85696037 0.02615177 0.57562388 1.393769
65 NM_001153 307 ANXA4 -6.81486949 0.00480461 0.57562388 1.391089
66 NM_014261 148022 TRIF -3.34138669 0.03873248 0.57562388 1.372367
67 NM_001679 483 ATP1B3 -4.27153073 0.01957329 0.57562388 1.355509
68 XM_084445 0 LOC143158 -2.98769674 0.05190017 0.57562388 1.345385
69 NM_014293 23467 NPTXR -2.15248569 0.11256347 0.57562388 1.334069
70 NM_016564 51286 BM88 -3.35160412 0.03841764 0.57562388 1.327834
71 NM_021974 5435 POLR2F -5.15746533 0.01125474 0.57562388 1.324421
72 NM_005227 1945 EFNA4 -2.94870315 0.05366827 0.57562388 1.322891
73 XM_171060 253639 ZNF620 -2.98942432 0.05182349 0.57562388 1.319373
74 NM_007366 22925 PLA2R1 -1.90267617 0.14517907 0.57562388 1.315942
75 NM_016451 1315 COPB -6.05761956 0.00691252 0.57562388 1.313703
76 NM_018489 55870 ASH1L -3.66636985 0.03010497 0.57562388 1.312102
77 NM_017836 54946 SLC41A3 -2.82474999 0.05979943 0.57562388 1.306341
78 NM_016265 51711 ZNF325 -5.46897849 0.00943564 0.57562388 1.290793
79 NM_006083 3550 IK -1.55011729 0.21107258 0.57815733 1.281843
80 NM_197964 154791 HSPC268 -7.09941456 0.00422968 0.57562388 1.277608
81 NM_005649 6940 ZNF354A -12.97474 0.00061838 0.4422131 1.274754
82 XM_047083 0 LOC92755 -5.22650515 0.01081538 0.57562388 1.271161
83 NM_023016 65124 C2ORF26 -4.58047237 0.01598583 0.57562388 1.262959
84 NM_024080 79054 TRPM8 -5.68480042 0.00839159 0.57562388 1.261654
85 NM_022567 60506 NYX -2.44227707 0.08488551 0.57562388 1.261258
86 NM_024110 79092 CARD14 -4.38344954 0.01816612 0.57562388 1.260132
87 NM_080622 140701 C20ORF135 -3.26487621 0.04119461 0.57562388 1.259969
88 NM_003412 7545 ZIC1 -5.69805753 0.0083324 0.57562388 1.257849
89 XM_371488 0 LOC388939 -3.80604727 0.02714073 0.57562388 1.256481
90 NM_021126 4357 MPST -2.48506252 0.08152102 0.57562388 1.25445
91 NM_001386 1808 DPYSL2 -1.79513373 0.16245974 0.57562388 1.253711
92 XM_116971 196993 LOC196993 -5.99521954 0.00713533 0.57562388 1.249537
93 NM_007346 11054 OGFR -2.04389282 0.12557562 0.57562388 1.243349
94 NM_018593 117247 SLC16A10 -19.4232316 0.0001666 0.4422131 1.238147
95 NM_021251 11132 CAPN10 -9.91634157 0.00146898 0.48351905 1.235937
96 NM_016202 51157 ZNF580 -4.24964459 0.01986439 0.57562388 1.234412
97 NM_000813 2561 GABRB2 -2.45012084 0.08425647 0.57562388 1.229346
98 NM_022304 3274 HRH2 -2.96054945 0.05312343 0.57562388 1.2278
99 NM_004545 4707 NDUFB1 -2.28057738 0.09918687 0.57562388 1.224029
100 NM_020348 26507 CNNM1 -5.85645855 0.00766479 0.57562388 1.214948
101 NM_014665 9684 LRRC14 -2.1628459 0.11140613 0.57562388 1.213947
102 NM_006233 5438 POLR2I -3.79511793 0.0273591 0.57562388 1.207967
103 NM_003427 7629 ZNF76 -7.46438207 0.00361552 0.57562388 1.207862
104 NM_015319 23371 TENC1 -2.27547182 0.09968299 0.57562388 1.207848
105 NM_017990 55066 PDPR -2.66570027 0.06896577 0.57562388 1.207647
106 XM_379840 0 LOC402509 -1.99226053 0.13236811 0.57562388 1.206983
107 NM_004390 1512 CTSH -9.72230391 0.0015648 0.48351905 1.206209
108 NM_174925 205251 LOC205251 -1.61282562 0.19726718 0.57687699 1.202894
109 NM_014569 23660 ZFP95 -3.63808964 0.03075364 0.57562388 1.199439
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110 NM_000687 191 AHCY -8.34814439 0.00254103 0.55902722 1.196668
111 XM_379501 0 LOC401367 -3.80278079 0.02720576 0.57562388 1.195346
112 NM_022751 64762 C18ORF11 -2.63693947 0.07080022 0.57562388 1.193569
113 NM_001655 372 ARCN1 -2.95930319 0.05318043 0.57562388 1.192574
114 NM_002140 3190 HNRPK -1.67582881 0.18438349 0.57562388 1.191434
115 NM_017776 55634 FLJ20344 -2.79877068 0.06119076 0.57562388 1.191049
116 NM_078483 206358 SLC36A1 -4.25959507 0.01973137 0.57562388 1.185451
117 NM_006462 10616 C20ORF18 -1.67075795 0.18538545 0.57562388 1.181995
118 NM_015305 23357 KIAA0759 -4.51726915 0.01664724 0.57562388 1.177352
119 NM_001535 3275 HRMT1L1 -3.63869781 0.03073951 0.57562388 1.177119
120 NM_198504 344838 PAQR9 -3.90083673 0.02533551 0.57562388 1.175835
121 NM_016305 51188 SS18L2 -3.46051434 0.03525117 0.57562388 1.169052
122 NM_002594 5126 PCSK2 -2.96625187 0.05286357 0.57562388 1.165381
123 NM_198401 157567 LOC157567 -2.29361856 0.0979328 0.57562388 1.15347
124 NM_002951 6185 RPN2 -4.2776666 0.01949265 0.57562388 1.150616
125 NM_006253 5564 PRKAB1 -1.56186399 0.2084088 0.57815733 1.149823
126 NM_020847 27327 TNRC6 -4.96675671 0.01259255 0.57562388 1.146274
127 NM_022156 64118 PP3111 -2.28145635 0.09910176 0.57562388 1.145053
128 NM_003951 9016 SLC25A14 -1.46238852 0.23216203 0.57827016 1.131503
129 NM_014033 25840 DKFZP586A0522-4. 3024689 0.02012698 0.57562388 1.127486
130 NM_002434 4350 MPG -2.64846459 0.07005813 0.57562388 1.127265
131 NM_004500 3183 HNRPC -1.24510371 0.29450435 0.59440153 1.126523
132 NM_031309 83482 SCRT1 -4.61941634 0.01559483 0.57562388 1.119456
133 NM_001762 908 CCT6A -10.3758286 0.00127059 0.48351905 1.115444
134 NM_014632 9645 MICAL2 -1.49889769 0.22312365 0.57815733 1.114972
135 NM_178858 118980 SFXN2 -5.20676911 0.01093871 0.57562388 1.114772
136 NM_145255 124995 MRPL10 -4.27088466 0.0195818 0.57562388 1.113375
137 NM_023068 6614 SN -2.83063494 0.05948962 0.57562388 1.112715
138 NM_002826 5768 QSCN6 -2.23004916 0.10422787 0.57562388 1.110032
139 NM_024763 79819 FLJ23129 -3.06810863 0.04847403 0.57562388 1.109393
140 NM_130807 126308 MOBKL2A -4.90361462 0.01307976 0.57562388 1.107674
141 NM_021620 59336 PRDM13 -1.8137446 0.15930989 0.57562388 1.105833
142 NM_015004 23016 EXOSC7 -2.04695013 0.12518619 0.57562388 1.103749
143 NM_024627 79680 FLJ21125 -2.07443711 0.12174701 0.57562388 1.100817
144 XM_380120 0 LOC402537 -3.91332864 0.02510898 0.57562388 1.100767
145 NM_144639 131669 FLJ31300 -5.53303853 0.0091092 0.57562388 1.093867
146 NM_002068 2769 GNA15 -4.31370168 0.01902742 0.57562388 1.090654
147 XM_371501 200424 MGC22014 -2.40138711 0.08825678 0.57562388 1.090504
148 NM_015642 26137 ZNF288 -2.08669924 0.12024813 0.57562388 1.08555
149 NM_021009 7316 UBC -8.39703059 0.00249449 0.55902722 1.085506
150 NM_003002 6392 SDHD -1.70681852 0.17838861 0.57562388 1.074185
151 NM_017534 4620 MYH2 -8.45971107 0.00243641 0.55902722 1.070938
152 NM_001299 1264 CNN1 -1.45831629 0.23319405 0.57836885 1.068407
153 NM_002419 4296 MAP3K11 -4.2569195 0.01976703 0.57562388 1.068129
154 NM_004062 1014 CDH16 -2.43842145 0.08519676 0.57562388 1.067915
155 NM_024031 78994 MGC3121 -3.09888164 0.04723672 0.57562388 1.064762
156 NM_003311 7262 PHLDA2 -1.78268786 0.16460517 0.57562388 1.064221
157 NM_031421 83538 DKFZP434H0115-2.29483934 0.09781636 0.57562388 1.057592
158 NM_004741 9221 NOLC1 -2.24000078 0.10321163 0.57562388 1.057478
159 NM_002645 5286 PIK3C2A -4.9645125 0.01260946 0.57562388 1.055754
160 NM_013265 738 C11ORF2 -1.60521498 0.19888909 0.57687699 1.054983
161 NM_152544 152992 FLJ23861 -1.74649826 0.1710259 0.57562388 1.049267
162 NM_207477 400931 FLJ27365 -3.74661682 0.02835516 0.57562388 1.048371
163 NM_031287 83443 SF3B5 -2.17542124 0.11001995 0.57562388 1.042922
164 NM_014325 23603 CORO1C -3.36723109 0.03794221 0.57562388 1.041365
165 NM_006645 10809 STARD10 -1.8128112 0.15946623 0.57562388 1.040594
